Global high consequence infectious disease events: summary June 2024
Updated 6 August 2024
Global high consequence infectious disease events: summary June 2024
Interpreting this report
The report provides updates on known, high consequence infectious disease (HCID) events around the world as monitored by UK Health Security Agency’s (UKHSA) epidemic intelligence activities.
The report is divided into 2 sections covering all the defined HCID pathogens. The first section contains contact and airborne HCIDs that have been specified for the HCID programme by NHS England. The second section contains additional HCIDs that are important for situational awareness.
Each section contains information on known pathogens and includes descriptions of recent events. If an undiagnosed disease event occurs that could be interpreted as a potential HCID, a third section will be added to the report.
Events found during routine scanning activities that occur in endemic areas will briefly be noted in the report. Active surveillance, other than daily epidemic intelligence activities, of events in endemic areas will not be conducted (for example, actively searching government websites or other sources for data on case numbers).
The target audience for this report is any healthcare professional who may be involved in HCID identification, treatment and management.
Risk rating
Included for each disease is a current risk rating based on the probability of introduction to the UK and potential impact on the UK public. Past UK experience and the global occurrence of travel-associated cases are also considered. Currently, all diseases are classified into one of 3 categories: Low, very low and exceptionally low to negligible.
Incidents of significance of primary HCIDs
Contact HCIDs
Crimean-Congo haemorrhagic fever (CCHF)
Geographical risk areas | Endemic in Africa, the Balkans, the Middle East and western and south-central Asia. Cases have also been reported in Russia and Georgia. Spain has previously reported locally acquired cases (first reported in 2016, with the latest case reported in 2024) . |
---|---|
Sources and routes of infection | • bite from, or crushing of, an infected tick • contact with the blood, tissues or body fluids of infected humans or animals |
UK experience to date | Two cases have been reported in individuals who have travelled to the UK from Afghanistan in 2012 and Bulgaria in 2014. |
Risk rating | Low – rarely reported in travellers. |
Recent cases or outbreaks | Between 1 January and 29 June 2024, the World Health Organization (WHO) reported 470 CCHF cases (123 confirmed), including 35 deaths (case fatality rate (CFR) of 10.8%), from Afghanistan. Confirmed cases were reported from 8 provinces including Kabul, Kunduz, Balkh, Kapisa, Helmand, Baghlan, Takhar, and Paktika. In 2023, Afghanistan reported 1,243 CCHF cases (383 confirmed), including 114 deaths (CFR of 9.2%). According to media on 27 June 2024, 23 CCHF cases and 4 deaths have been reported in the Dhi Qar Province of Iraq during 2024. A further 10 cases and 2 associated deaths were reported in Nineveh Province. On 28 June 2024, media reported that the Kurdistan Regional Government Ministry of Health had registered 5 CCHF cases so far in 2024. In 2024, up to 4 June 2024, North Macedonia’s Institute of Public Health has reported 3 confirmed cases of CCHF nationally. All of the cases were hospitalised for treatment, with 2 cases reporting exposure to ticks. During June 2024, media reported one CCHF case in Quetta, and 6 cases in Balochistan, Pakistan. A total of 13 CCHF cases, including one death have been reported in Pakistan so far in 2024. In Russia, on 18 June 2024, media reported 10 CCHF cases in the Rostov region. Media also reported one case in the Republic of Dagestan, and 2 cases in the Astrakhan region. During 2023, 26 CCHF cases were reported in Russia. In the Tokat Region of Turkey, 40 CCHF cases have been reported between 1 January and 26 June 2024. According to media, fatal cases were reported in Cankri (one case) and Sivas (4 cases) regions. On 16 June 2024, the Africa Centres for Disease Control and Prevention reported 10 CCHF cases, including 6 deaths, from Uganda so far in 2024. The cases were reported from Kasese (one case) and Kiruhura (4 cases including 3 deaths) and Lyantonde (5 cases and 3 deaths) districts. |
Ebola virus disease (EVD)
Geographical risk areas | Map of countries which have reported EVD cases up to January 2023. No outbreaks of EVD have since been reported. |
---|---|
Sources and routes of infection | • contact with blood, tissues or body fluids of infected animals, or consumption of raw or undercooked infected animal tissue • contact with infected human blood or body fluids |
UK experience to date | Four confirmed cases (one lab-acquired in the UK in 1976, 3 healthcare workers associated with West African epidemic 2014 to 2015). |
Risk rating | Very low – other than during the West Africa outbreak, exported cases are extremely rare. |
Recent cases or outbreaks | No confirmed or suspected human cases were reported in June 2024. |
Lassa fever
Geographical risk areas | Endemic in sub-Saharan West Africa. |
---|---|
Sources and routes of infection | • contact with excreta, or materials contaminated with excreta from an infected rodent • inhalation of aerosols of excreta from an infected rodent • contact with infected human blood or body fluids |
UK experience to date | Three travel-related Lassa fever cases reported in 2022. Prior to this, 8 imported Lassa fever cases had been reported since 1980, all in travellers from West Africa. |
Risk rating | Low – overall, Lassa fever is the most common imported viral haemorrhagic fever (VHF) but importations to the UK are still rare. |
Recent cases or outbreaks | Between 1 January and 7 June 2024, Liberia reported 44 Lassa fever cases (13 confirmed; 31 suspected), including 4 deaths. This outbreak began in January 2022. Between 1 January and 23 June 2024, Nigeria reported 920 confirmed and 6,902 suspected Lassa fever cases. 162 deaths were reported amongst confirmed cases (CFR of 17.6%). This is a lower CFR compared to the same period in 2023 (20.0%). Confirmed cases have been reported from 28 out of 36 states. |
Marburg virus disease (MVD)
Geographical risk areas | Sporadic outbreaks have previously been reported in Central and Eastern Africa. A human case of MVD was reported in August 2021 in Guinea; this was the first case to be identified in West Africa. MVD cases were reported in Ghana for the first time in July 2022. MVD outbreaks were reported for the first time in Equatorial Guinea in February 2023 and in Tanzania in March 2023. |
---|---|
Sources and routes of infection | • exposure in mines or caves inhabited by Rousettus bat colonies • contact with infected human blood or body fluids |
UK experience to date | No reported cases in the UK. |
Risk rating | Very low – globally, 5 travel-related exported MVD cases have previously been reported in the literature. |
Recent cases or outbreaks | No confirmed or suspected human cases were reported in June 2024. |
Airborne HCIDs
Avian influenza A(H7N9) virus
Geographical risk areas | All reported human infections have been acquired in China. | |
---|---|---|
Sources and routes of infection | • close contact with infected birds or their environments • close contact with infected humans (no sustained human-to-human transmission) |
|
UK experience to date | No known cases in the UK. | |
Risk rating | Very low (UKHSA risk assessment). | |
Recent cases or outbreaks | No confirmed or suspected human cases were reported in June 2024. |
Avian influenza A(H5N1) virus
Geographical risk areas | Human cases have been predominantly reported in South East Asia, but also in Egypt, Iraq, Pakistan, Turkey and Nigeria. Human cases (clade 2.3.4.4b) were reported in Spain and the USA in 2022 and 2024, and in the UK in 2022 and 2023. The first human cases of avian influenza A(H5N1) (clade 2.3.4.4b) were reported from South America in 2023, from Ecuador and Chile. Since October 2023, several human cases of clade 2.3.2.1c have been reported in Cambodia. |
---|---|
Sources and routes of infection | • close contact with infected animals (notably birds) or their environments • close contact with infected humans (no sustained human-to-human transmission) |
UK experience to date | As of September 2023, 5 detections were reported in the UK, one in 2022 and 4 in 2023. |
Risk rating | Very low (UKHSA risk assessment). |
Recent cases or outbreaks | No confirmed or suspected human cases were reported in June 2024. Since March 2024, detections of avian influenza A(H5N1) have been reported in dairy cattle in the United States (US). To the end of May 2024, 3 associated human cases were reported in individuals with exposure to infected cattle. No associated human cases were reported during June 2024. For further information see the US Centres for Disease Control and Prevention H5 Bird Flu: Current Situation webpage. |
Middle East respiratory syndrome (MERS-CoV)
Geographical risk areas | The Arabian Peninsula – Bahrain, Jordan, Iraq, Kingdom of Saudi Arabia, Kuwait, Oman, Qatar, United Arab Emirates, Yemen. Evidence has also been reported in Iran and Kenya. |
---|---|
Sources and routes of infection | • airborne particles • direct contact with contaminated environment • direct contact with camels or consumption of raw camel milk |
UK experience to date | Five MERS-CoV cases in total – 3 imported cases (2012, 2013 and 2018), 2 secondary cases in close family members of the case in 2013, 3 deaths. |
Risk rating | Very low (UKHSA risk assessment). |
Recent cases or outbreaks | No confirmed or suspected human cases were reported in June 2024. |
Mpox (Clade I only)
Geographical risk areas | Central Africa including, Central African Republic, Cameroon, the Democratic Republic of the Congo (DRC), Gabon and Republic of the Congo. |
---|---|
Sources and routes of infection | • close contact with an infected animal (in an endemic country) or an infected person • contact with clothing or linens (such as bedding or towels) used by an infected person • direct contact with mpox skin lesions or scabs • coughing or sneezing of an individual with an mpox rash • consumption of contaminated bushmeat |
UK experience to date | No cases of Clade I mpox have been reported in the UK. |
Risk rating | Very low – no known importations of Clade I mpox into the UK. |
Recent cases or outbreaks | Sequencing data is often not available for mpox cases reported from endemic African countries where Clade I mpox virus is known to circulate. Therefore, we report below all reported mpox cases from these countries, regardless of whether the samples have been sequenced or clade-tested. Between 1 January and 16 June 2024, the Democratic Republic of the Congo (DRC) reported 9,192 mpox cases (1,030 confirmed), including 419 deaths (CFR of 4.6%), from 23 out of 26 provinces. During 2023, the DRC reported its highest annual number of mpox cases (14,434 cases, including 728 deaths). In the Republic of the Congo, as of 21 June 2024, 146 mpox cases (19 confirmed) and one death were reported from 5 out of 12 provinces. During 2023, 95 mpox cases, including 5 deaths were reported. |
Nipah virus
Geographical risk areas | South East Asia, predominantly in Bangladesh and India. Cases have also been reported in Malaysia and Singapore. |
---|---|
Sources and routes of infection | • direct or indirect exposure to infected bats • consumption of contaminated raw date palm sap • close contact with infected pigs or humans |
UK experience to date | No known cases in the UK. |
Risk rating | Exceptionally low to negligible – no travel-related infections in the literature. |
Recent cases or outbreaks | No confirmed cases of Nipah virus infection were reported in June 2024. |
Pneumonic plague (Yersinia pestis)
Geographical risk areas | Predominantly sub-Saharan Africa but also Asia, North Africa, South America, Western USA. Endemic in Madagascar, Peru, and the DRC. |
---|---|
Sources and routes of infection | • flea bites • close contact with infected animals • close contact with human cases of pneumonic plague |
UK experience to date | Last outbreak in the UK was in 1918. |
Risk rating | Exceptionally low to negligible |
Recent cases or outbreaks | On 4 July 2024, media reported a confirmed human case of plague in Colorado State, US. The article does not specify the type of plague that was detected. An average of 7 human plague cases are reported annually in the US. |
Severe acute respiratory syndrome (SARS)
Geographical risk areas | Currently none. Two historical outbreaks originating from China in 2002 and 2004. |
---|---|
Sources and routes of infection | • airborne particles • direct contact with contaminated environment |
UK experience to date | Four imported SARS cases related to the 2002 outbreak. |
Risk rating | Exceptionally low to negligible |
Recent cases or outbreaks | No confirmed or suspected human cases reported globally since 2004. |
Incidents of significance of additional HCIDs
Argentine haemorrhagic fever (Junin virus)
Geographical risk areas | Argentina (central). Endemic to the provinces of Buenos Aires, Córdoba, Santa Fe and La Pampa. |
---|---|
Sources and routes of infection | • direct contact with infected rodents • inhalation of infectious rodent fluids and excreta • person-to-person transmission has been documented |
UK experience to date | No known cases in the UK. |
Risk rating | Exceptionally low to negligible – one travel-related case was identified in Belgium in 2020. |
Recent cases or outbreaks | In 2024, up to 22 June 2024, the Buenos Aires Province Ministry of Health, Argentina, reported 13 confirmed and 51 suspected cases of Argentine haemorrhagic fever, including 2 deaths. During the equivalent period in 2023, 4 confirmed and 98 suspected cases were reported in Buenos Aires. |
Bolivian haemorrhagic fever (Machupo virus)
Geographical risk areas | Bolivia – cases have been identified in the departments of Beni (Mamoré, Iténez and Yucuma provinces) and Cochabamba (Cercado province). |
---|---|
Sources and routes of infection | • direct contact with infected rodents • inhalation of infectious rodent fluids and excreta • person-to-person transmission has been documented |
UK experience to date | No known cases in the UK. |
Risk rating | Exceptionally low to negligible – travel-related cases have never been reported. |
Recent cases or outbreaks | No confirmed or suspected human cases were reported in June 2024. |
Lujo virus disease
Geographical risk areas | A single case acquired in Zambia led to a cluster in South Africa in 2008. |
---|---|
Sources and routes of infection | • presumed rodent contact (excreta, or materials contaminated with excreta of infected rodent) • person to person via body fluids |
UK experience to date | No known cases in the UK. |
Risk rating | Exceptionally low to negligible – a single travel-related case has been reported. No cases have been reported anywhere since 2008. |
Recent cases or outbreaks | No cases have been reported anywhere since 2008. |
Severe fever with thrombocytopenia syndrome (SFTS)
Geographical risk areas | Mainly reported from China (south-eastern), Japan and Korea. Cases have also been reported in Taiwan, Thailand, Myanmar and Vietnam. Serological evidence of SFTS in Pakistan. |
---|---|
Sources and routes of infection | • presumed to be tick exposure • person-to-person transmission described in household and hospital contacts, via contact with blood or bloodstained body fluids |
UK experience to date | No known cases in the UK. |
Risk rating | Exceptionally low to negligible – not known to have occurred in travellers. |
Recent cases or outbreaks | Between January and June 2024, the Korean Disease Control and Prevention Agency reported 33 SFTS cases. This is a lower number of cases reported compared to the equivalent 2023 period (46 cases). |
Andes virus (Hantavirus)
Geographical risk areas | Chile and Southern Argentina. |
---|---|
Sources and routes of infection | • rodent contact (excreta, or materials contaminated with excreta from an infected rodent) • person-to-person transmission described in household and hospital contacts |
UK experience to date | No known cases in the UK. |
Risk rating | Very low – rare cases in travellers have been reported. |
Recent cases or outbreaks | On 13 June 2024, media reported 7 cases of hantavirus in Jujuy Province, Argentina, since the beginning of 2024. A fatal case was reported by media in Rio Negro Province, on 20 June 2024. Neither article specified the type of hantavirus. |
Avian influenza A(H5N6) virus
Geographical risk areas | Mostly China. New strain reported in Greece in March 2017, and subsequently found in Western Europe in birds. |
---|---|
Sources and routes of infection | Close contact with infected birds or their environments. |
UK experience to date | No known cases in the UK. |
Risk rating | Very low – not known to have occurred in travellers (UKHSA risk assessment). |
Recent cases or outbreaks | During June 2024, one fatal human case of avian influenza A(H5N6) was reported from Fujian Province, China. The source of infection remains unknown. Since 2014, up to 13 June 2024, 92 confirmed human cases of avian influenza A(H5N6), including 37 deaths (case fatality rate of 40%) have been reported in the WHO Western Pacific Region. |
Avian influenza A(H7N7) virus
Geographical risk areas | Sporadic occurrence in birds across mainland Europe and the UK. A human case was reported in Ireland in 1996, 89 cases were reported in the Netherlands in 2003, and 3 human cases were reported in Italy in 2013. |
---|---|
Sources and routes of infection | • close contact with infected birds or their environments • close contact with infected humans (no sustained human-to-human transmission reported) |
UK experience to date | No known cases in the UK. |
Risk rating | Very low – human cases are rare, and severe disease even rarer. |
Recent cases or outbreaks | No confirmed or suspected human cases were reported in June 2024. |
Authors of this report
Emerging Infections and Zoonoses Team, UKHSA.